作者：
Dobo,K.L. [1]
;
Greene,N. [2]
;
Fred,C. [3]
;
Glowienke,S. [4]
;
Harvey,J.S. [5]
;
Hasselgren,C. [6]
;
Jolly,R. [7]
;
Kenyon,M.O. [8]
;
Munzner,J.B. [9]
;
Muster,W. [10]
;
Neft,R. ;
VijayarajReddy,M. ;
White,A.T. ;
Weiner,S.
作者单位：
Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340, United States
[1]
Eli Lilly and Company, Indianapolis, IN 46285, United States
[2]
Johnson and Johnson Drug Safety Sciences, Route 202 South, Raritan, NJ 08869, United States
[3]
GlaxoSmithKline, Park Road, Ware, Herts SG12 0DP, United Kingdom
[4]
Covance Laboratories Inc., 671 South Meridian Road, Greenfield, IN 46140, United States
[5]
Merck Research Laboratories, West Point, PA 19486, United States
[6]
F. Hoffmann-La Roche Ltd., Pharma Research and Early Development, CH-4070 Basel, Switzerland
[7]
Safety Assessment, AstraZeneca R and D S?dert?lje, 151 85 S?dert?lje, Sweden
[8]
Novartis Pharma AG, Werk Klybeck, Klybeckstrasse 141, CH-4057 Basel, Switzerland
[9]
Global Safety Assessment, AstraZeneca R and D, S-431 83 M?lndal, Sweden
[10]
发布时间
2013-11-20
换一批
